About Us
Insmed Incorporated (NASDAQ: INSM) is a development stage biopharmaceutical company with expertise in proprietary, advanced liposomal technology designed specifically for inhalation lung delivery.
We are focusing on markets with high unmet medical needs, orphan markets which present a significant opportunity to Insmed, as their challenge and complexity best fit our knowledge, know-how and expertise.
At Insmed, our vision emphasizes developing safe and effective medicines for those orphan diseases and conditions in which patient needs are currently unmet, such as Pseudomonas lung infections in cystic fibrosis (CF) patients and nontuberculous mycobacteria (NTM) lung infections.
Our lead compound, ARIKACE™ (liposomal amikacin for inhalation), is a differentiated, inhaled antibiotic supported by positive phase II results for treating serious lung infections due to susceptible bacteria. We believe ARIKACE has potential usage in at least two orphan indications with high unmet-needs that we believe have a well defined regulatory path towards approval. Insmed intends to initiate phase III studies during 2011 for ARIKACE in treating CF patients with Pseudomonas lung infections and patients with NTM lung infections. In addition to these two target indications, ARIKACE has potential to be used for treating other types of conditions, such as non-CF bronchiectasis patients that have Pseudomonas lung infections, for which we also have orphan drug status.
Please revisit us here at this site for future updates on our progress.
